Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
about
Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapyThe treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesThe GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityA novel, long-acting glucagon-like peptide receptor-agonist: dulaglutideAdverse Effects of GLP-1 Receptor AgonistsDulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetesBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingEfficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic reviewClinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patientsDrug-induced liver injury: Towards early prediction and risk stratificationMedical Management of Diabesity: Do We Have Realistic Targets?Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemStudy protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.Incretin-based therapies in prediabetes: Current evidence and future perspectivesEfficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned CatsThe risk of pancreatitis with sitagliptin therapy in older adults: a population-based cohort studyAssessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'Prescribing differences in family practice for diabetic patients in Germany according to statutory or private health insurance: the case of DPP-4-inhibitors and GLP-1-agonists.Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.Toxic-metabolic Risk Factors in Pediatric Pancreatitis: Recommendations for Diagnosis, Management, and Future Research.Diabetes medications: Impact on inflammation and wound healingDipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort StudyAlpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysisIncretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies.Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy.A review of gliptins for 2014.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Exocrine pancreatic insufficiency in diabetic patients: prevalence, mechanisms, and treatment.Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
P2860
Q26739888-FB0477CB-94B2-44D3-9129-8C8BE12D9C1FQ26744317-06CE56D9-1FD5-4A14-83D9-A0248C81DD75Q26765609-A47EA9CA-BB0D-4E14-BBE8-AD707F88DBDAQ26796417-895CA4A8-3318-4162-A02D-AF6071683A4FQ26801346-480EF6BA-5395-469E-B292-D36D59D7EE8EQ26861768-521530DB-CD1E-46CD-B07C-CFAB79513A4BQ26992979-D0F5BB86-F1F5-4E5C-A3F0-0902D26719B0Q28076726-6A4B2D64-1D19-43A3-BB62-42EE1A1586E2Q28083144-32901A8D-FF31-4B26-A140-2562AF9E79D5Q28468389-4A49A66A-1001-41CD-9CE3-4B7CF3AA3ADDQ30238940-12CA973E-4E46-440E-94BF-C4F959420675Q30249371-8A51869D-3092-42C4-99CF-30612ABFDE93Q30848457-20018D98-B278-43F3-8C17-3A52DADC3585Q31066859-4AD9AF89-DDEC-4035-985C-B641CA58DF75Q31167862-4C0A4668-032B-425B-99F9-D396299442ADQ33874654-67CEDF12-BBB7-4D86-8D28-A8FB184A07BBQ34062829-2075DB64-9CAE-47D4-837F-18554FA171BBQ34558740-BF06287E-3EDF-4033-9763-559FFD0E80F3Q34559981-606DE759-4A37-4297-9454-EA06C2E8C005Q34699191-4CC5E7A3-8698-4438-B48D-90C60D8D07F0Q35331836-EEBB237D-6061-4EDC-8D77-50D6465B0D77Q36005314-CE4A81B1-87F3-40DA-BB13-E3CDDEC99E31Q36064999-F60C0427-DA20-49D2-A658-C38F8E503EB0Q36073447-D964A48F-63BB-4A61-AB9E-F89AABDA7A32Q36168227-9C328D06-729C-4AF2-8C3C-E0C74B262113Q36327126-CEE00AF8-330F-47D3-8968-111017F14F6DQ36723036-C54F830F-177A-4C0B-867C-104C01E9F46FQ36805643-DCC623C8-6535-4F3B-96D7-0BD8F66D4D3DQ37206067-DD2EF136-2339-4328-A495-67D8B8E6C7DEQ37232678-94FE3684-D264-4FD6-B86D-403276010AA2Q37427294-EB7AEB39-691F-41BA-B2ED-70E7ABEDE4B5Q37696559-7695CF6A-8721-4F58-80E1-4E57ECED67D6Q38255715-0B42BDE2-A4C2-4802-B12B-AD3120C42839Q38264360-DF63035C-AA59-4030-AD8F-34626AC99BE3Q38264376-03F52C51-1038-4682-A03B-379460652784Q38266290-C4B2D15F-E2DC-43A7-BDF7-5276740073AAQ38286444-C80F4266-61EE-42A2-B2B3-1A389928424FQ38335751-B35B7B08-19F3-4FC3-97B9-9015E5FAB9CFQ38429521-F84481FA-2A7D-41A5-885C-F2E120FC3767Q38455771-9619077C-734C-4109-BD70-63A52BCA7861
P2860
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Incretin treatment and risk of ...... sed and non-randomised studies
@ast
Incretin treatment and risk of ...... sed and non-randomised studies
@en
Incretin treatment and risk of ...... sed and non-randomised studies
@nl
type
label
Incretin treatment and risk of ...... sed and non-randomised studies
@ast
Incretin treatment and risk of ...... sed and non-randomised studies
@en
Incretin treatment and risk of ...... sed and non-randomised studies
@nl
prefLabel
Incretin treatment and risk of ...... sed and non-randomised studies
@ast
Incretin treatment and risk of ...... sed and non-randomised studies
@en
Incretin treatment and risk of ...... sed and non-randomised studies
@nl
P2093
P2860
P31
P50
P921
P3181
P356
P1433
P1476
Incretin treatment and risk of ...... sed and non-randomised studies
@en
P2093
Evelyn Wong
German Malaga
Jiantong Shen
Lorena P Rios
Malgorzata M Bala
Shanil Ebrahim
Zahra Sohani
P2860
P3181
P356
10.1136/BMJ.G2366
P407
P433
P5008
P577
2014-04-15T00:00:00Z